S
Stockadora
IPO Journey

Parabilis Medicines, Inc.

IPO Date: June 10, 2026 · 5 filings tracked

Final Offer Terms

Ticker
PBLS
Exchange
The Nasdaq Global Select Market
Offer Price
$20.00
Shares Offered
33,500,000
Estimated Proceeds
$670.0M
Underwriters

Led by Leerink Partners, BofA Securities

Filing Timeline

1
S-1
May 19, 2026
  • Proprietary AI platform 'Helicon' targets previously 'undruggable' biological targets
  • Strategic partnership and $75M equity investment from Regeneron Pharmaceuticals
View full analysis → SEC filing ↗
2
S-1/A
May 27, 2026
  • Strategic License and Collaboration Agreement with Regeneron Pharmaceuticals
  • Proprietary platform for precision medicine in cancer and immune disorders

Changes from previous filing

  • ▸ Ticker symbol removed
View full analysis → SEC filing ↗
3
S-1/A
June 4, 2026
  • Proprietary 'Helicon' technology platform targeting previously 'undruggable' proteins.
  • Strategic partnership with Regeneron Pharmaceuticals, including $50M upfront and $75M investment.

Changes from previous filing

  • ▸ Ticker symbol: PBLS
  • ▸ Exchange: The Nasdaq Global Market
  • ▸ Expected offer range: $17.0 – $19.0 per share
  • ▸ Shares offered: 25,000,000
  • ▸ Estimated proceeds: $425M
View full analysis → SEC filing ↗
4
S-1/A
June 9, 2026
  • Proprietary 'Helicon' platform targets previously 'undruggable' proteins
  • Lead candidate zolucatetide addresses rare, aggressive desmoid tumors

Changes from previous filing

  • ▸ Shares offered: 33,333,334
  • ▸ Estimated proceeds: $566M
View full analysis → SEC filing ↗
424B4 Final Pricing
June 10, 2026
  • Backed by industry giant Regeneron Pharmaceuticals with a $75M private investment
  • Led by CEO Dr. Mathai Mammen, who oversaw 19 successful drug approvals

Changes from previous filing

  • ▸ Exchange: The Nasdaq Global Select Market
  • ▸ Price range removed
  • ▸ Final offer price: $20.0 per share
  • ▸ Shares offered: 33,500,000
  • ▸ Estimated proceeds: $670M
  • ▸ Underwriters: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital
View full analysis → SEC filing ↗
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.